We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+5.74%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.25B
AUM Growth
-$166M
Cap. Flow
+$57.7M
Cap. Flow %
2.57%
Top 10 Hldgs %
71.88%
Holding
46
New
3
Increased
7
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
GNCA
Genocea Biosciences, Inc.
GNCA
+$26M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$14.3M
3
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$13.2M
4
ADAP
Adaptimmune Therapeutics
ADAP
+$11.4M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$10.9M

Top Sells

Rank Stock Value
1
CASC
Cascadian Therapeutics, Inc.
CASC
+$33.5M
2
ORKA
Oruka Therapeutics
ORKA
+$1.97M
3
OREX
Orexigen Therapeutics, Inc.
OREX
+$478K

Sector Composition

Rank Sector Weight
1 Healthcare 91.74%
2 Technology 1.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHXM
26
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$13.1M 0.58%
62,500
– –
RIGL icon
27
Rigel Pharmaceuticals
RIGL
$727M
$11.5M 0.51%
324,315
– –
DZSI
28
DELISTED
DZS Inc. Common Stock
DZSI
$10.9M 0.49%
956,255
– –
ELGX
29
DELISTED
Endologix Inc
ELGX
$10.5M 0.47%
249,020
– –
NITE
30
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$10.2M 0.45%
714,285
– –
AFMD
31
DELISTED
Affimed
AFMD
$9.51M 0.42%
513,889
+125,000
+32% +$2.36M
TRIL
32
DELISTED
Trillium Therapeutics Inc.
TRIL
$9M 0.4%
1,250,000
– –
TNTR
33
DELISTED
Tintri, Inc. Common Stock
TNTR
$8.98M 0.4%
5,253,358
– –
TCON
34
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$7.97M 0.35%
17,336
+3,540
+26% +$1.93M
RGLS
35
DELISTED
Regulus Therapeutics
RGLS
$7.88M 0.35%
91,583
– –
ARQL
36
DELISTED
Arqule Inc
ARQL
$7.26M 0.32%
2,520,316
– –
MDB icon
37
MongoDB
MDB
$30.4B
$6.51M 0.29%
150,000
– –
TRVN
38
DELISTED
Trevena, Inc.
TRVN
$6.25M 0.28%
6,099
– –
CSBR icon
39
Champions Oncology
CSBR
$75.9M
$5.69M 0.25%
1,562,500
– –
AQ
40
DELISTED
Aquantia Corp. Common Stock
AQ
$3.76M 0.17%
239,587
– –
VIRX
41
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.53M 0.16%
37,094
– –
AKTX
42
Akari Therapeutics
AKTX
$13.2M
$823K 0.04%
565
– –
AYTU icon
43
AYTU BioPharma
AYTU
$23.9M
$29K ﹤0.01%
+11
New +$75.7K
ORKA
44
Oruka Therapeutics
ORKA
$5.9B
– –
-6,760
Closed -$1.97M
CASC
45
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-9,064,575
Closed -$33.5M
OREX
46
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-370,900
Closed -$478K
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
GD
Grandfield & Dodd New York $1.77B AUM 23.43% 1-Year Est. Return
DF
DNCA Finance Paris, France $1.75B AUM 38.18% 1-Year Est. Return

NEA Management Company's Q1 2018 Portfolio in Review

As of Q1 2018, NEA Management Company held 46 positions worth $2.25B, down 6.9% from $2.41B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

NEA Management Company's Q1 2018 filing shows 3 new, 7 increased and 3 closed positions. Its largest new stake was Genocea Biosciences, Inc.: 3,125,000 shares worth $26.3M. The largest sale was Cascadian Therapeutics, Inc., an estimated $33.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier, followed by Technology.

  • NEA Management Company's largest Q1 2018 buy was Genocea Biosciences, Inc.: 3,125,000 shares worth $26.3M.
  • NEA Management Company added most to Ra Pharmaceuticals, Inc. Common Stock in Q1 2018, an estimated $14.3M increase.
  • NEA Management Company fully exited Cascadian Therapeutics, Inc. in Q1 2018, selling an estimated $33.5M.
  • NEA Management Company's ten largest holdings make up 72% of its $2.25B portfolio in Q1 2018.
  • NEA Management Company opened 3 new positions and closed 3 in Q1 2018.
  • NEA Management Company's portfolio value fell 6.9% quarter-over-quarter to $2.25B.

Based on NEA Management Company's 13F filing for Q1 2018, filed 10 May 2018.